Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer

Cancer Research

Volumn 72, Issue 16, 2012, Pages 4141-4153

  Szabova, Ludmila ^a   Yin, Chaoying ^c   Bupp, Sujata ^a   Guerin, Theresa M ^a   Schlomer, Jerome J ^a   Householder, Deborah B ^a   Baran, Maureen L ^a   Yi, Ming ^a   Song, Yurong ^b,c   Sun, Wenping ^a   McDunn, Jonathan E ^d   Martin, Philip L ^a   Van Dyke, Terry ^a,b,c   Difilippantonio, Simone ^a  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d METABOLON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DISTANT METASTASIS; EPITHELIUM; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; METABOLOMICS; METASTASIS POTENTIAL; MISSENSE MUTATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; SEROUS EPITHELIAL OVARIAN CANCER; TISSUE GROWTH;

ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; DISEASE MODELS, ANIMAL; FEMALE; GENE DELETION; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865140569     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3834     Document Type: Article

References (49)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 2009;27:2686-91.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. (Pubitemid 40310185)
4. Neesham D. Ovarian cancer screening. Aust Fam Physician 2007; 36:126-8.
5. Cesario S. Advances in the early detection of ovarian cancer: How to hear the whispers early. Nurs Womens Health 2010;14: 222-34.
6. The Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
7. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002;108:135-44. (Pubitemid 34161134)
8. Sharpless NE, Depinho RA. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 2006;5:741-54. (Pubitemid 44323701)
9. Olive KP, Tuveson DA. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 2006;12:5277-87. (Pubitemid 44497240)
10. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-33. (Pubitemid 46518315)
11. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003;63: 3459-63. (Pubitemid 36793020)
12. Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, et al. Development of a syngeneic mouse model of epithelial ovarian cancer. J Ovarian Res 2010;3:24.
13. Clark-Knowles KV, Senterman MK, Collins O, Vanderhyden BC. Conditional inactivation of Brca1, p53 and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One 2009;4: e8534.
14. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63:1389-97. (Pubitemid 36348722)
15. Quinn BA, Brake T, Hua X, Baxter-Jones K, Litwin S, Ellenson LH, et al. Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PLoS One 2009;4:e8404.
16. Xing D, Orsulic S. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Cancer Res 2006;66: 8949-53. (Pubitemid 44521109)
17. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15.
18. Stubdal H, Zalvide J, Campbell KS, Schweitzer C, Roberts TM, DeCaprio JA. Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol Cell Biol 1997;17:4979-90. (Pubitemid 27357597)
19. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, et al. Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev 2000;14: 3037-50.
20. Simin K, Hill R, Song Y, Zhang Q, Bash R, Cardiff RD, et al. Deciphering cancer complexities in genetically engineered mice. Cold Spring Harb Symp Quant Biol 2005;70:283-90. (Pubitemid 44124882)
21. Lozano G. The oncogenic roles of p53 mutants in mouse models. Curr Opin Genet Dev 2007;17:66-70. (Pubitemid 46109293)
22. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005;65:10280-8. (Pubitemid 41743720)
23. Feki A, Irminger-Finger I. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004;52: 103-16. (Pubitemid 39419493)
24. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr, Park SH, et al. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog 1995;14:16-22.
25. Bell-McGuinn KM, Leitao MM. Surface epithelial tumors: clinical introduction. In: Soslow RA, Tornos C, editors. Diagnostic pathology of ovarian tumors. New York (NY): Springer; 2011. p. 47-54.
26. Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 2003;13:125-9. (Pubitemid 37055465)
27. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001;116: 246-52. (Pubitemid 33044330)
28. Hwang H, Quenneville L, Yaziji H, Gown AM. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004;12:122-6. (Pubitemid 38788760)
29. Ordonez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-14. (Pubitemid 28462768)
30. Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 2010;34:627-35.
31. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, et al. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 2010;9:140-6.
32. Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, et al. Immunophenotyping of serous carcinoma of the female genital tract. Mod Pathol 2008;21:1147-55.
33. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007;31: 1139-48. (Pubitemid 47207115)
34. Barnetson RJ, Burnett RA, Downie I, Harper CM, Roberts F. Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum: antibodies to estrogen and progesterone receptors are useful. Am J Clin Pathol 2006;125: 67-76. (Pubitemid 43089727)
35. Yi M, Stephens RM. SLEPR: a sample-level enrichment-based pathway ranking method-seeking biological themes through pathway-level consistency. PLoS One 2008;3:e3288.
36. Davidson B, Zhang Z, Kleinberg L, Li M, Florenes VA, Wang TL, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2006;12:5944-50. (Pubitemid 44703753)
37. Fong MY, McDunn J, Kakar SS. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 2011;6:e19963.
38. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC. Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007; 313:133-45. (Pubitemid 44958459)
39. Ho VM, Schaffer BE, Karnezis AN, Park KS, Sage J. The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. Oncogene 2009;28: 1393-9.
40. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010;70:3877-83.
41. Sood AK, Sorosky JI, Dolan M, Anderson B, Buller RE. Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 1999;5:2485-90. (Pubitemid 29437332)
42. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30. (Pubitemid 36530000)
43. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010;2010:932371.
44. Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 2010;34:1407-16.
45. Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol 2009;33:1878-85.
46. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185-92.
47. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-90. (Pubitemid 47477278)
48. Agoff SN, Mendelin JE, Grieco VS, Garcia RL. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol 2002;26: 171-8. (Pubitemid 34127496)
49. Karst AM, Levanon K, Drapkin R. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 2011;108:7547-52.